Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma
Batool Shannan(Vrije Universiteit Brussel), Alexander Roesch(Essen University Hospital), Jochen Utikal(German Cancer Research Center), Thomas G. P. Grünewald(German Cancer Research Center), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Renáta Váraljai(Vrije Universiteit Brussel), Verena Jendrossek(German Cancer Research Center), Susanne Horn(Vrije Universiteit Brussel), Felix C. E. Vogel(German Cancer Research Center), Andrea Forschner(University of Tübingen), David Rafei‐Shamsabadi(University Medical Center Freiburg), Giuseppina Sannino(Ludwig-Maximilians-Universität München), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Joachim Klode(Essen University Hospital), Ricarda Rauschenberg(National Center for Tumor Diseases), Lucie Heinzerling(LMU Klinikum), Johann Matschke(Essen University Hospital), Johannes Bruns(National Center for Tumor Diseases), Elisabeth Livingstone(German Cancer Research Center), Dana Westphal(Helmholtz-Zentrum Dresden-Rossendorf), Björn Scheffler(German Cancer Research Center), Carola Berking(Universitätsklinikum Erlangen), Lisa Zimmer(The University of Sydney), A. Hoewner(University of Duisburg-Essen), Evelyn Dabrowski(Klinikum Ludwigshafen), Martin Stuschke(Essen University Hospital), Aruna Marchetto(Ludwig-Maximilians-Universität München), Diana Klein(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Heike Chauvistré(Essen University Hospital), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k